NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Formats Text Remove constraint Formats: Text Copyright Copyright may apply Remove constraint Copyright: Copyright may apply Recently Added Within 6 Months Remove constraint Recently Added: Within 6 Months

Search Results

64. Gene therapies for sickle cell disease: final evidence report

65. Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH): final evidence report

66. Lecanemab for early Alzheimer’s disease: final evidence report

67. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report

68. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report

69. Tezepelumab for severe asthma: final report

70. Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value : final evidence report

71. Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report

72. Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

73. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma: final report

74. Health care affordability improved between 2019 and 2022 under pandemic health coverage policies: findings from the Well-Being and Basic Needs Survey

78. Coverage and cost effects of Senators Merkley and Murphy’s Choose Medicare Act

80. Evaluating California’s efforts to address the commercial sexual exploitation of children